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SUMMARY
Due to its prevalence, impact on quality-of-life and the
associated significant health resource utilization, dys-
pepsia is a major healthcare concern. The available
management strategies for uninvestigated dyspepsia
include prompt endoscopy, the ‘test-and-treat’ strategy
for Helicobacter pylori, and empiric antisecretory ther-
apy. There is consensus that endoscopy should be
reserved for patients with alarm features (e.g. symptom
onset after 45 years of age, recurrent vomiting, weight
loss, dysphagia, evidence of bleeding, anaemia),
H. pylori-positive individuals who fail test-and-treat,
and those with an inadequate response to empiric
antisecretory therapy. Factors influencing the decision
between test-and-treat and empiric antisecretory ther-
apy in uninvestigated dyspepsia include the local
prevalence of H. pylori and peptic ulcer disease and
the proportion of ulcers attributable to H. pylori. For
uninvestigated dyspepsia in patients without alarm
features, test-and-treat is the preferred initial manage-
ment method in Europe based on the relatively high
prevalence of H. pylori/peptic ulcer disease whereas
empiric antisecretory therapy is preferred in many parts
of the United States, where the prevalence of H. pylori/
peptic ulcer disease is relatively low. In patients with
non-ulcer dyspepsia, H. pylori eradication and empiric
antisecretory therapy result in comparable and small,
but statistically significant, improvements in dyspepsia.
Empiric antisecretory therapy is the preferred initial
method of managing non-ulcer dyspepsia in Europe and
the US. The test-and-treat approach would receive
increased enthusiasm if H. pylori cure is shown to
prevent development of gastric cancer in non-ulcer
dyspepsia patients in a large Western trial.
INTRODUCTION
Dyspepsia, defined as chronic or recurrent pain or
discomfort centred in the upper abdomen1 is an
extremely common disorder in otherwise healthy
individuals. An estimated 25% of adults in the US
and other Western countries suffer from recurrent
dyspepsia.2 Although less than half of those with
symptoms seek medical care3–6 dyspepsia accounts for
up to 5% of all primary care physician visits7, 8 and
billions of dollars in direct and indirect healthcare
expenditures. Furthermore, dyspepsia substantially
diminishes the quality-of-life and sense of well-being
of affected persons.9, 10
Differentiating between uninvestigated dyspepsia and
non-ulcer or functional dyspepsia is important in the
selection and expected outcomes of specific therapies.
Correspondence to: Professor W. D. Chey, Department of Internal Medicine,
Division of Gastroenterology, University of Michigan Medical Center, 3912
Taubman Center, Ann Arbor, MI 48109–0362, USA.
E-mail: wchey@umich.edu
Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 1–8.
 2004 Blackwell Publishing Ltd 1
Uninvestigated dyspepsia includes all symptomatic
patients, regardless of whether an aetiology has been
sought. Among those with dyspeptic symptoms,
approximately 60% have non-ulcer dyspepsia,2 a con-
dition in which an organic cause (e.g. acid-mediated
condition, motility disorder) of upper gastrointestinal
symptoms has been excluded. In a study of 1866
American patients with dyspepsia who underwent
endoscopy, 28% and 11% of patients were determined
to have acid- and nonacid-related disorders (e.g.
irritable bowel syndrome, gallstones), respectively,
causing their symptoms, whereas no structural explan-
ation for symptoms was found in 61%.11 Dyspepsia
results from disturbances in gastrointestinal motility,
visceral sensation, gastric accommodation, intestino-
gastric reflexes, gastric acid sensitivity and psychosocial
factors.2 In addition, a small, but statistically significant
relationship between Helicobacter pylori infection and
dyspepsia has been observed (relative risk of dyspep-
sia ¼ 1.21 [95% CI, 1.09–1.34] in H. pylori-positive
patients).12 Given the complex interplay of causes, no





The available management strategies for individuals
with uninvestigated dyspepsia include prompt endo-
scopy, the ‘test-and-treat’ strategy for H. pylori, and
empiric antisecretory therapy. Endoscopy yields the
greatest diagnostic certainty, directs targeted medical
therapy (with the potential for fewer prescriptions),
and provides reassurance to both the patient and
physician. The cost and small associated risk of com-
plications as well as lack of infrastructure necessary to
endoscope all patients with uninvestigated dyspepsia,
however, make endoscopy practical only for selected
patients. While each of the three management options
of uninvestigated dyspepsia have advantages and
disadvantages, there is broad consensus that endo-
scopy should be reserved for patients with symptom
onset after 45–50 years of age, those who have other
alarm features (e.g. recurrent vomiting, weight loss,
dysphagia, evidence of bleeding, or anaemia), and
those who fail empiric antisecretory therapy or the
test-and-treat strategy.2, 13, 14
Test-and-treat strategy
Multiple European guidelines and recommendations
from the American Gastroenterological Association
advocate the test-and-treat strategy for H. pylori as
initial management for younger patients with uncom-
plicated uninvestigated dyspepsia.13–15 The age cut-off
(i.e. less than 45 years old) varies among countries
depending on the incidence of gastric cancer.
Test-and-treat is a non-invasive approach which,
compared to prompt endoscopy, leads to similar clinical
outcomes while reducing endoscopy workload.16 A
Cochrane systematic review identified four randomized,
controlled trials in which H. pylori test-and-treat was as
effective as endoscopy at reducing dyspepsia at 1 year
(relative risk of dyspepsia cure 1.01 [95% CI 0.84–
1.22]).16 Only 23% (95% CI 12%–44%) of patients
allocated to H. pylori test-and-treat required endoscopy
over a 1-year follow-up, while almost every patient
randomized to early endoscopy had this procedure.16
There is also evidence from randomized controlled trials
of the impact of H. pylori eradication in reducing
dyspepsia symptoms (number needed to treat ¼ 7) and
the reassurance value of a negative test (number needed
to test ¼ 9).17 Helicobacter pylori testing is less expensive
than endoscopy and there is a relatively high H. pylori/
peptic ulcer prevalence in Europe, therefore test-and-
treat is the most cost-effective strategy in most European
countries. As the prevalence of H. pylori falls in patients
with dyspepsia, as is the case in many parts of the US,
economic models suggest that empiric acid suppression
therapy becomes the most cost-effective method of
managing dyspepsia.18, 19
There are several drawbacks to the test-and-treat
strategy for uninvestigated dyspepsia. For instance, test-
and-treat leads to symptom resolution in fewer than
50% of infected uninvestigated dyspepsia patients,20, 21
the poor results being related to the relatively small
percentage of patients with peptic ulcer disease and the
marginal benefit of H. pylori eradication in patients with
functional dyspepsia.20–23, 40 In a recently published
paper of two randomized, double-blind clinical studies
evaluating the impact of H. pylori eradication therapy
on symptoms of functional dyspepsia (ORCHID and
OCAY, n ¼ 718), there was no difference in response
(defined as no or minimal symptoms 12 months after
completion of treatment) between H. pylori-negative
and -positive patients (30% and 23%, respectively).23 It
is noteworthy that after being tested for H. pylori and
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treated as necessary, patients may be less satisfied with
their care as compared to those undergoing endo-
scopy.24 As a result, endoscopy may be ultimately
avoided in only a minority of patients. Furthermore,
cure of H. pylori infection may result in worsening GERD
symptoms,25 although this is the subject of considerable
debate.26, 27
Empiric antisecretory therapy
Empiric antisecretory or prokinetic therapy has long
been employed as an initial management option in
younger patients with uncomplicated uninvestigated
dyspepsia and is likely cost-effective in geographical
areas of low H. pylori/peptic ulcer disease prevalence
(e.g. the US). Empiric pharmacologic therapy is
embraced by many, based on affordability when
drugs are only used intermittently, the long-term
safety profile, and widespread availability of many
agents through ‘over-the-counter’ access. Empiric
antisecretory therapy has been criticized for poten-
tially delaying the diagnosis of important organic
disease (i.e. gastric cancer). Concern for this approach
also stems from the potential for inappropriate,
chronic medication usage in patients with potentially
curable conditions such as H. pylori-related peptic
ulcer disease.
Antisecretory agents have a central role in the initial
treatment of patients with uninvestigated dyspepsia.
Few studies have directly compared agents. In a study of
H. pylori-negative patients with uninvestigated dyspep-
sia from the CADET-HN study, proton pump inhibitors
were found to be more effective than histamine-2
receptor antagonists for dyspeptic symptoms (24% vs.
11%, respectively, complete symptom relief at 4 weeks,
P < 0.005) (Figure 1).28 Likewise, in a double-blind,
randomized, multicentre study of patients with acid-
related dyspepsia (reflux-like or ulcer-like symptoms)
conducted in the UK, superior symptom relief was
observed among patients treated with lansoprazole as
compared to ranitidine (69% and 44%, respectively, of
patients symptom-free at 4 weeks, P ¼ 0.001).29
Test-and-treat vs. empiric antisecretory therapy
Several factors influence the choice between the test-
and-treat strategy and empiric antisecretory therapy in
patients with uninvestigated dyspepsia. These include
the local prevalence of H. pylori and peptic ulcer disease,
the proportion of ulcers attributable to H. pylori, as well
as the cost and success of diagnostic testing and
therapy. The clinical benefits of test-and-treat in
patients with uninvestigated dyspepsia are primarily
based on those from curing peptic ulcer disease, with
only a small benefit in patients with non-ulcer dyspepsia
(as described below). The economic implication of the
two competing strategies for uninvestigated dyspepsia
was evaluated in a cost-minimization analysis model in
which proton pump inhibitor treatment was consis-
tently less costly than test-and-treat when the H. pylori
prevalence was less than 20%.18 According to three-
way sensitivity analysis, test-and-treat is favoured in
geographical areas where ulcer or H. pylori prevalence,
which usually track together, are high (as is the case in
many European countries), whereas empiric antisecre-
tory therapy is favoured when the prevalence rates are
low (as in the case in many regions of the US). When
following a test-and-treat strategy, the positive predic-
tive value of antibody testing is directly related to
H. pylori prevalence, falling dramatically when the
H. pylori prevalence is less than 50%.30 Decision
analytic modelling reveals that active tests (e.g. urea
breath test, stool antigen test) dramatically reduce
inappropriate H. pylori treatment for patients without
infection, when compared with antibody testing, at an
incremental cost of $37 per patient.31
The challenge to clinicians and policy-makers is that
these variables are in flux. For example, costs of
Figure 1. Percentages of H. pylori-negative patients with unin-
vestigated dyspepsia who experienced complete symptom relief
after 4 weeks of treatment with a proton pump inhibitor, a
histamine-2 receptor antagonist, cisapride, or placebo. The
significantly greater effects of proton pump inhibitor therapy
compared to all other treatments and histamine-2 receptor
antagonist therapy compared to placebo are illustrated in this
study.28
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antisecretory agents may fall with the introduction of
generic products within a category (e.g. omeprazole in
the US). Epidemiologic data suggest that the prevalence
of both H. pylori and peptic ulcer disease is waning in the
US.32 In addition, it is clear that in certain regions of the
world, the original reports33 showing an H. pylori
prevalence of 90% in patients with peptic ulcer disease
are overstated. Given falling proton pump inhibitor costs
and decreasing H. pylori and ulcer prevalence, empiric
antisecretory therapy is likely to be more cost effective
than the test-and-treat strategy for uninvestigated
dyspepsia in various geographical areas such as the US.
The cost effectiveness of combining these strategies
prior to endoscopy requires further study. A recent
decision analytic model found that a strategy consisting
of initial test-and-treat for H. pylori, followed by empiric
proton pump inhibitor therapy in nonresponders, and
endoscopy only for patients with persistent dyspeptic
symptoms may be more cost-effective than test-and-
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Figure 2. Proposed management algorithm for patients with uninvestigated dyspepsia. Endoscopy is recommended in those > 45 years of
age or with alarm features (includes unexplained weight loss, recurrent vomiting, dysphagia, evidence of anaemia or gastrointestinal
bleeding, or an abdominal mass or lymphadenopathy) and those who are unresponsive to proton pump inhibitor therapy and/or the
test-and-treat strategy. This figure has been modified and reprinted from: American Gastroenterological Association. Medical position
statement: evaluation of dyspepsia. Gastroenterology 1998; 114: 579–581, with permission from American Gastroenterological
Association.14
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tunately, this strategy requires that all patients with
uninvestigated dyspepsia undergo testing for H. pylori,
the prevalence of which is relatively low in countries
such as the US. In addition, we have mentioned that the
greatest benefit of test-and-treat is derived from the
fewer than 20% of infected patients with peptic ulcer
disease, because the benefit of H. pylori eradication in
functional dyspepsia is, at best, small. With this in mind,
an alternative strategy that requires consideration
would be initial empiric proton pump inhibitor therapy
with test-and-treat reserved only for treatment respond-
ers (Figure 2). Endoscopy would be recommended for
those unresponsive to proton pump inhibitor therapy.
By only performing test-and-treat in those responsive to
proton pump inhibitor therapy, such a strategy would
enrich the population of dyspeptic patients most likely to
be suffering with H. pylori-related acid–peptic disease
(peptic ulcer disease and acid-related functional dys-
pepsia). Further studies evaluating the optimal combi-
nation and sequence of approaches in patients with
uninvestigated dyspepsia are eagerly awaited.
MANAGEMENT STRATEGIES FOR NON-ULCER
DYSPEPSIA
There are a variety of therapeutic modalities available to
clinicians. Agents that affect gastric accommodation or
nociception deserve further study; at present the two
main strategies for therapy in non-ulcer dyspepsia are
H. pylori eradication and antisecretory therapy.
Helicobacter pylori eradication
Treatment of non-ulcer dyspepsia is controversial, with
randomized controlled trials and systematic reviews
giving conflicting results. A UK systematic review of
nine studies suggested that H. pylori eradication was
beneficial in infected non-ulcer dyspepsia patients
(relative risk reduction of remaining dyspeptic 9%
[95% CI 4–14%]).34 Even when a study with a large
effect size was omitted, a statistically significant differ-
ence favouring H. pylori eradication over placebo was
observed.35 In contrast, a meta-analysis from the US,
which included seven randomized controlled trials,
found no benefit from the use of H. pylori eradication
therapy in patients with non-ulcer dyspepsia (Odds ratio
for dyspepsia cure 1.3, 95% CI 0.9–1.9).20 When the
two reviews were compared, six differences in meth-
odology were found.36 The most important difference
between the two reviews was the date of the search,
with the US review concluding in December 1999 and
the UK review concluding in May 2000. This difference
resulted in the UK review evaluating more trials and
including data from 997 additional patients. This gave
the UK meta-analysis sufficient power to detect the
small effect of H. pylori eradication on non-ulcer
dyspepsia. When studies published through May 2000
were included in the US review (which added four
trials), H. pylori eradication had a small, but statistically
significant effect on dyspepsia symptoms (Odds ratio
1.4; 95% CI 1.2–1.7) and heterogeneity disappeared
(heterogeneity statistic P ¼ 0.24).
The effect size of H. pylori eradication on non-ulcer
dyspepsia was small (numbers needed to treat ¼ 15;
95% CI 10–31),34 which begs the question ‘Is H. pylori
eradication a cost-effective strategy for non-ulcer dys-
pepsia patients?’. Economic modelling (over a 12-month
time frame) using the UK data and previously published
methodology37 suggests that H. pylori eradication has a
50% chance of being cost-effective compared with
antacid therapy, provided the third-party payer or
patient is willing to spend 26 euros per dyspepsia-free
month, or has a 95% chance of being cost-effective with
the willingness to spend at least 52 euros per dyspepsia-
free month.34 The test-and-treat strategy is most
affordable in Spain and Germany, among European
countries, and least affordable in the US, where one
must be willing to spend approximately $300 for every
month free from dyspepsia before the strategy can be
confidently considered cost-effective.
Antisecretory therapy
Many patients will fail to respond to H. pylori eradication
or will be H. pylori-negative. Antisecretory therapy is
utilized by many clinicians in these circumstances.
Based on the results of a meta-analysis, including seven
studies and 3241 treated patients, proton pump inhib-
itor therapy may be effective in non-ulcer dyspepsia
(Figure 3) (33% and 23% response rates with proton
pump inhibitor and placebo, respectively; relative risk
reduction 14% [95% CI 5–23%]), although there was
substantial heterogeneity among trials.38 This hetero-
geneity was not explained by differences in studies
conducted in the US and Europe, patterns of H. pylori, or
prevalence of reflux-like symptoms. The risk ratio for
remaining dyspeptic is similar between high- and low-
dose proton pump inhibitor regimens.38 This was also
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shown in two randomized, double-blind studies in which
the complete symptom relief rate with lansoprazole
15 mg or 30 mg given for 8 weeks was significantly
higher than that with placebo in patients with non-ulcer
dyspepsia, with no difference in response between the
low- and high-dose proton pump inhibitor regimen.39
The effect size with antisecretory therapy (number
needed to treat ¼ 9; 95% CI 6–26) was larger than with
H. pylori eradication.38 The cost-effectiveness, however,
varies widely among European countries; depending on
the local cost of proton pump inhibitor therapy, because
the drug needs to be given continuously to cure
symptoms. Economic modelling (over a 12-month time
frame using high-dose proton pump inhibitor) suggests
that proton pump inhibitor treatment for non-ulcer
dyspepsia is most affordable in Spain and Germany, as
was the case with test-and-treat, and least affordable in
the US, where one must be willing to spend approxi-
mately $500 for every month free from dyspepsia before
the strategy can be confidently considered cost-effective
compared with antacid therapy.
CONCLUSIONS
H. pylori testing and treatment and empirical antisecre-
tory therapy are both valid approaches to the manage-
ment of uninvestigated dyspepsia. The choice will
depend on the prevalence of peptic ulcer disease and
H. pylori in the setting that the strategy is being
considered. Some patients will eventually have endo-
scopy despite these initial management strategies. The
most common diagnosis will be non-ulcer dyspepsia and
again the most appropriate therapies are H. pylori
eradication (if the patient is infected) and antisecretory
agents. The benefits in curing H. pylori patients vs.
non-ulcer dyspepsia will be modest, but other potential
benefits should also be borne in mind. Recent data
from Japan suggest potential benefits of H. pylori cure as
a chemopreventive strategy for gastric cancer in func-
tional dyspepsia patients.40 Confirmation of this finding
in a large Western trial would influence the enthusiasm
for pursuing H. pylori in non-ulcer dyspepsia patients.
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